FDA Approves First Breast Cancer Drug to Target PIK3CA Mutation Plus Companion Diagnostic Test - https://t.co/aKeLjhpYhA Managed Markets Network https://t.co/EX4nTlsrug
— IDRO (@IDROOhio) May 29, 2019
from Twitter https://twitter.com/IDROOhio
May 28, 2019 at 04:54PM
No comments:
Post a Comment